Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Progress in Drug Research PDF full book. Access full book title Progress in Drug Research by Ernst Jucker. Download full books in PDF and EPUB format.
Author: Ernst Jucker Publisher: Springer Science & Business Media ISBN: 9783764362669 Category : Medical Languages : en Pages : 316
Book Description
Progress in Drug Research is a prestigious book series which provides extensive expert-written reviews on a wide spectrum of highly topical areas in current pharmaceutical and pharmacological research. It serves as an important source of information for researchers concerned with drug research and all those who need to keep abreast of the many recent developments in the quest for new and better medicines.
Author: Ernst Jucker Publisher: Springer Science & Business Media ISBN: 9783764362669 Category : Medical Languages : en Pages : 316
Book Description
Progress in Drug Research is a prestigious book series which provides extensive expert-written reviews on a wide spectrum of highly topical areas in current pharmaceutical and pharmacological research. It serves as an important source of information for researchers concerned with drug research and all those who need to keep abreast of the many recent developments in the quest for new and better medicines.
Author: Institute of Medicine Publisher: National Academies Press ISBN: 0309292492 Category : Medical Languages : en Pages : 107
Book Description
Improving and Accelerating Therapeutic Development for Nervous System Disorders is the summary of a workshop convened by the IOM Forum on Neuroscience and Nervous System Disorders to examine opportunities to accelerate early phases of drug development for nervous system drug discovery. Workshop participants discussed challenges in neuroscience research for enabling faster entry of potential treatments into first-in-human trials, explored how new and emerging tools and technologies may improve the efficiency of research, and considered mechanisms to facilitate a more effective and efficient development pipeline. There are several challenges to the current drug development pipeline for nervous system disorders. The fundamental etiology and pathophysiology of many nervous system disorders are unknown and the brain is inaccessible to study, making it difficult to develop accurate models. Patient heterogeneity is high, disease pathology can occur years to decades before becoming clinically apparent, and diagnostic and treatment biomarkers are lacking. In addition, the lack of validated targets, limitations related to the predictive validity of animal models - the extent to which the model predicts clinical efficacy - and regulatory barriers can also impede translation and drug development for nervous system disorders. Improving and Accelerating Therapeutic Development for Nervous System Disorders identifies avenues for moving directly from cellular models to human trials, minimizing the need for animal models to test efficacy, and discusses the potential benefits and risks of such an approach. This report is a timely discussion of opportunities to improve early drug development with a focus toward preclinical trials.
Author: Publisher: Birkhäuser ISBN: 3034887353 Category : Medical Languages : en Pages : 287
Book Description
Hypertension is one of the cardiovascular diseases which is most common throughout the world. It is generally defined as an elevation of systolic and/or diastolic arterial blood pressure, which is 120/80 mm Hg in normal situation. A value of 140/90 mm is generally accepted as the upper limit of normotension. Hypertension with certain risk factors such as hypercholes terolemia, diabetes, smoking and a family history of vascular disease pre disposes to arteriosclerosis and consequent cardiovascular morbidity and mortality. The treatment of hypertension leads to reduced risk of hyperten sive renal failure, haemorrhagic stroke, myocardial infarction and cardiac failure. In most cases, the cause of the hypertension can not be clearly defined. Such hypertension is termed as essential hypertension. In a few cases (5- 15%), the hypertension is secondary to definable causes, such as renal artery stenosis, a pheochromocytoma, or an endocrine disorder. This type of hyper tension is known as secondary hypertenSion. Although the exact etiology of essential hypertension is still not well known, the following factors are sup posed to play causative roles.
Author: National Academies of Sciences, Engineering, and Medicine Publisher: National Academies Press ISBN: 0309498511 Category : Medical Languages : en Pages : 103
Book Description
To explore the role of the National Institutes of Health (NIH) in innovative drug development and its impact on patient access, the Board on Health Care Services and the Board on Health Sciences Policy of the National Academies jointly hosted a public workshop on July 24â€"25, 2019, in Washington, DC. Workshop speakers and participants discussed the ways in which federal investments in biomedical research are translated into innovative therapies and considered approaches to ensure that the public has affordable access to the resulting new drugs. This publication summarizes the presentations and discussions from the workshop.
Author: Benjamin E. Blass Publisher: Academic Press ISBN: 0128172150 Category : Science Languages : en Pages : 738
Book Description
Basic Principles of Drug Discovery and Development presents the multifaceted process of identifying a new drug in the modern era, which requires a multidisciplinary team approach with input from medicinal chemists, biologists, pharmacologists, drug metabolism experts, toxicologists, clinicians, and a host of experts from numerous additional fields. Enabling technologies such as high throughput screening, structure-based drug design, molecular modeling, pharmaceutical profiling, and translational medicine are critical to the successful development of marketable therapeutics. Given the wide range of disciplines and techniques that are required for cutting edge drug discovery and development, a scientist must master their own fields as well as have a fundamental understanding of their collaborator's fields. This book bridges the knowledge gaps that invariably lead to communication issues in a new scientist's early career, providing a fundamental understanding of the various techniques and disciplines required for the multifaceted endeavor of drug research and development. It provides students, new industrial scientists, and academics with a basic understanding of the drug discovery and development process. The fully updated text provides an excellent overview of the process and includes chapters on important drug targets by class, in vitro screening methods, medicinal chemistry strategies in drug design, principles of in vivo pharmacokinetics and pharmacodynamics, animal models of disease states, clinical trial basics, and selected business aspects of the drug discovery process. - Provides a clear explanation of how the pharmaceutical industry works, as well as the complete drug discovery and development process, from obtaining a lead, to testing the bioactivity, to producing the drug, and protecting the intellectual property - Includes a new chapter on the discovery and development of biologics (antibodies proteins, antibody/receptor complexes, antibody drug conjugates), a growing and important area of the pharmaceutical industry landscape - Features a new section on formulations, including a discussion of IV formulations suitable for human clinical trials, as well as the application of nanotechnology and the use of transdermal patch technology for drug delivery - Updated chapter with new case studies includes additional modern examples of drug discovery through high through-put screening, fragment-based drug design, and computational chemistry
Author: Ernst Jucker Publisher: Birkhäuser ISBN: 3034881711 Category : Medical Languages : en Pages : 291
Book Description
Nikolaus Seiler, Benoit Duranton and Francis Raul: The polyamine oxidase inactivator MDL 72527.- Zhi Hong and Craig E. Cameron: Pleiotropic mechanisms of ribavirin antiviral activities.- Jie Hong Hu and Charles Krieger: Protein phosphorylation networks in motor neuron death.- James O. Schenk: The functioning neuronal transporter for dopamine: kinetic mechanisms and effects of amphetamines, cocaine and methylphenidate.- Laszlo Prokai: Central nervous system effects of thyrotropin-releasing hormone and ist analogues: opportunities and perspectives for drug discovery and development.- David F. Horrobin: A new category of psychotropic drugs: neuroactive lipids as exemplified by ethyl eicosapentaenoate (E-E).- Suprabhat Ray, Reema Rastogi and Atul Kumar: Current status of estrogen receptors.
Author: Institute of Medicine Publisher: National Academies Press ISBN: 0309158060 Category : Medical Languages : en Pages : 442
Book Description
Rare diseases collectively affect millions of Americans of all ages, but developing drugs and medical devices to prevent, diagnose, and treat these conditions is challenging. The Institute of Medicine (IOM) recommends implementing an integrated national strategy to promote rare diseases research and product development.
Author: Giuseppe Di Giovanni Publisher: Elsevier ISBN: 0080932681 Category : Science Languages : en Pages : 682
Book Description
This book provides a unique and timely multidisciplinary synthesis of our current knowledge of the anatomy, pharmacology, physiology and behavioral data of the serotonin (5-HT)-dopamine (DA) interactions. Central serotonergic and dopaminergic systems play a critical role in the regulation of normal and abnormal behaviors. Moreover, recent evidence suggests that the dysfunction of the DA and 5-HT neurotransmitter systems contribute to various mental disorders including depression, schizophrenia, drug addiction and Parkinson's disease. This extremely important topic is of wide interest within the scientific community, with relevance not only to specialists but also to general practitioners and students. The book provides a valuable contribution to the debate on new pharmacological approaches for several psychopathological states, with contributions from expert neuroscientists and pharmacologists who comprehensively survey the most significant currently active areas of dopamine/serotonin interactions. - Provides an understanding of the interaction between Serotonin and Dopamine - Appeals equally to specialists, general practitioners, students and researchers - Contributes to the debate on new pharmacological approaches to several psychopathological states - Gives a comprehensive anatomical description plus the physiology and pharmacology of dopaminergic and serotonergic systems - Singles out neuropsychiatric and suggests new therapeutic approaches
Author: Ernst Jucker
Author: Ernst Jucker
Author: Institute of Medicine
Author: 
Author: National Academies of Sciences, Engineering, and Medicine
Author: JUCKER
Author: Benjamin E. Blass
Author: Ernst Jucker
Author: JUCKER
Author: Institute of Medicine
Author: Giuseppe Di Giovanni